Overview

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Celgene Corporation
Treatments:
Azacitidine
Lenalidomide
Thalidomide